Almirall Finalises Acquisition of Allergan US Medical Dermatology Portfolio.
25 September 2018 - Spain-based pharmaceutical company Almirall, S.A. has completed its acquisition of products from US-based Allergan's US Medical Dermatology unit, including Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid) and Cordran Tape (flurandrenolide), the company said.
Sarecycline, a new chemical entity currently under FDA review for approval in the treatment of acne, is also part of the transaction.
The transaction closed for a cash consideration of USD 550m. This agreement also contemplates a possible earn-out, up to USD 100m and payable in the first quarter of 2022, depending on business performance.
These portfolio additions further enhance Almirall's presence in the US dermatology space through their subsidiary Aqua Pharmaceuticals, a respected manufacturer of established therapies for a range of medical dermatology indications including acne, eczema, dermatitis, actinic keratoses and bacterial infections.
Almirall is a leading skin-health focussed global pharmaceutical company that partners with healthcare professionals, applying science to provide medical solutions to patients and future generations.
Aqua Pharmaceuticals was acquired by Almirall in 2013.
Target: Dermatology products, including Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid) and Cordran Tape (flurandrenolide)
Buyer: Almirall, S.A.
Deal size in USD: 550m
Type: Corporate Acquisition
Buyer advisor: , ,
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Sep 25, 2018|
|Previous Article:||Amynta Group to Expand Warranty/Service Contracts Portfolio with Acquisition of Guardsman.|
|Next Article:||Vista Global Acquires XOJET Fleet, Commercial Operations.|